PMR Press Release

<span class="entry-title-primary">Antibiotics Market Size to Reach 56.369.92 Million USD with 4.7% CAGR by 2024</span> <span class="entry-subtitle">Global Antibiotics Market</span><span class="rating-result after_title mr-filter rating-result-34729" >			<span class="no-rating-results-text">No ratings yet.</span>		</span>
Antibiotics Market Size to Reach 56.369.92 Million USD with 4.7% CAGR by 2024 Global Antibiotics Market

Global Antibiotics Market Overview:

The global antibiotics market was valued at USD 42.653.89 million in 2018, estimated at USD 56.369.92 million in 2024, a CAGR of 4.7%. Several other factors that drive the market growth include anti-MRSA drugs, generic drug development, and vulnerable aging population.

A company that first manufactured the patented drug tries to produce maximum income before the patent expires. Once the patent expires, many rivals start producing the generic formulations. They have the same pharmacological activity as the initial drug. Nearly 80% of prescription drugs are generic. The cost is therefore decreased. More individuals can afford drugs, leading to enhanced health results. Indiscriminate drug use, however, also contributes to drug resistance and complications.

Global Antibiotics Market Scope of the Report:As per the scope of the report, antibiotic medicines are among the most prescribed classes globally in combating bacterial infections, primarily in outpatient environments.

Global Antibiotics Market Key trends:

Carbapenems are expected to show Futures rapid growth.

During the forecast period, the cephalosporin section will account for the biggest market size. During the forecast period, Carbapenems will witness the greatest CAGR of around 5.9 percent.

The increasing risk of drug resistance and a fragile pipeline of fresh molecules lead to combinational formulations. For example, in nations like India, multi-drug-resistant tuberculosis TB is a significant factor in driving R&D spending. Methicillin-resistant Staphylococcus aureus MRSA is another bacterium responsible for several hard-to-treat human infections. Infection with MRSA is hard to treat with conventional antibiotics such as penicillin methicillin, dicloxacillin, nafcillin, oxacillin and cephalosporins. In 2014, the US Food and Drug Administration FDA approved four fresh antibiotics for the therapy of gram-positive diseases, including MRSA.

Get Detailed Information about this Research Report @ https://www.planetmarketreports.com/reports/global-antibiotics-market

North America is Expected to Dominate the Market in the Forecast Period:

North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds most of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to a decrease in the unemployment rate.

Global Antibiotics Market Competitive Landscape:

The antibiotics market is extremely competitive, with several key players. On market share, few significant players presently dominate the market. With technological advances and product innovations, mid-size to smaller companies increase their market presence by introducing fresh products at lower rates. Companies like GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc. hold important antibiotic market shares.

Contact Info:

Name: Jennifer Daniel
Email-Id: sales@planetmarketreports.com
US:  +1-716-2260907
UK: +447441952057
Organization: Planet Market Reports

Web | Facebook | Linkedin | Twitter

Please rate this

Leave a Reply

Close Menu